A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells - PubMed (original) (raw)
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells
Martin A Pulè et al. Mol Ther. 2005 Nov.
Free article
Abstract
The transduction of primary T cells to express chimeric T cell receptors (cTCR) for redirected targeting of tumor cells is an attractive strategy for generating tumor-specific T cells for adoptive therapy. However, tumor cells rarely provide costimulatory signals and hence cTCRs that transmit just a CD3zeta signal can only initiate target cell killing and interferon-gamma release and fail to induce full activation. Although incorporation of a CD28 component results in IL-2 release and limited proliferation, T cell activation remains incomplete. OX40 transmits a potent and prolonged T cell activation signal and is crucial for maintaining an immunological response. We hypothesize that the CD28-OX40-CD3zeta tripartite cytoplasmic domain will provide a full complement of activation, proliferation, and survival signals for enhanced anti-tumor activity.
Similar articles
- Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling.
Hombach AA, Abken H. Hombach AA, et al. Int J Cancer. 2011 Dec 15;129(12):2935-44. doi: 10.1002/ijc.25960. Epub 2011 Mar 29. Int J Cancer. 2011. PMID: 22030616 - CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack.
Chmielewski M, Hombach AA, Abken H. Chmielewski M, et al. Gene Ther. 2011 Jan;18(1):62-72. doi: 10.1038/gt.2010.127. Epub 2010 Oct 14. Gene Ther. 2011. PMID: 20944680 - Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells.
Watanabe K, Terakura S, Martens AC, van Meerten T, Uchiyama S, Imai M, Sakemura R, Goto T, Hanajiri R, Imahashi N, Shimada K, Tomita A, Kiyoi H, Nishida T, Naoe T, Murata M. Watanabe K, et al. J Immunol. 2015 Feb 1;194(3):911-20. doi: 10.4049/jimmunol.1402346. Epub 2014 Dec 17. J Immunol. 2015. PMID: 25520398 - The weal and woe of costimulation in the adoptive therapy of cancer with chimeric antigen receptor (CAR)-redirected T cells.
Hombach AA, Holzinger A, Abken H. Hombach AA, et al. Curr Mol Med. 2013 Aug;13(7):1079-88. doi: 10.2174/1566524011313070003. Curr Mol Med. 2013. PMID: 23116267 Review. - Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA, Reidy A, Mirandola L, Trotter K, Suvorava N, Figueroa A, Konala V, Aulakh A, Littlefield L, Grizzi F, Rahman RL, Jenkins MR, Musgrove B, Radhi S, D'Cunha N, D'Cunha LN, Hermonat PL, Cobos E, Chiriva-Internati M. Figueroa JA, et al. Int Rev Immunol. 2015 Mar;34(2):154-87. doi: 10.3109/08830185.2015.1018419. Int Rev Immunol. 2015. PMID: 25901860 Review.
Cited by
- Recent advancements in improving the efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy for hepatocellular carcinoma.
Ren T, Huang Y. Ren T, et al. Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep 24. doi: 10.1007/s00210-024-03443-7. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 39316087 Review. - Functional Activity of Cytokine-Induced Killer Cells Enhanced by CAR-CD19 Modification or by Soluble Bispecific Antibody Blinatumomab.
Zaninelli S, Panna S, Tettamanti S, Melita G, Doni A, D'Autilia F, Valgardsdottir R, Gotti E, Rambaldi A, Golay J, Introna M. Zaninelli S, et al. Antibodies (Basel). 2024 Aug 30;13(3):71. doi: 10.3390/antib13030071. Antibodies (Basel). 2024. PMID: 39311376 Free PMC article. - Conversion of anti-tissue factor antibody sequences to chimeric antigen receptor and bi-specific T-cell engager format.
Saunderson SC, Halpin JC, Tan GMY, Shrivastava P, McLellan AD. Saunderson SC, et al. Cancer Immunol Immunother. 2024 Aug 6;73(10):195. doi: 10.1007/s00262-024-03778-3. Cancer Immunol Immunother. 2024. PMID: 39105809 Free PMC article. - Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers.
Gargett T, Truong NTH, Gardam B, Yu W, Ebert LM, Johnson A, Yeo ECF, Wittwer NL, Tapia Rico G, Logan J, Sivaloganathan P, Collis M, Ruszkiewicz A, Brown MP. Gargett T, et al. J Immunother Cancer. 2024 May 15;12(5):e008659. doi: 10.1136/jitc-2023-008659. J Immunother Cancer. 2024. PMID: 38754916 Free PMC article. Clinical Trial. - A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives.
Montoya M, Gallus M, Phyu S, Haegelin J, de Groot J, Okada H. Montoya M, et al. Cells. 2024 Apr 23;13(9):726. doi: 10.3390/cells13090726. Cells. 2024. PMID: 38727262 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources